Compositions and methods for treating an autism spectrum disorder

Abstract

Disclosed are compositions and methods for the treatment of a subject having an autism spectrum disorder. The disclosed compositions may contain racemic ketamine or S-ketamine. The disclosed methods of administering the compositions include intranasal administration to a subject having an autism spectrum disorder.

1 .- 15 . (canceled) 
     
     
         16 . An intranasal delivery device comprising a composition comprising racemic ketamine, wherein said delivery device is capable of administering a unit dose of from about 20 to about 120 mg. 
     
     
         17 . The device according to  claim 16 , wherein said composition is substantially free of R-ketamine. 
     
     
         18 . The device according to  claim 16  wherein said device delivers a dose of from about 20 to about 120 mg. 
     
     
         19 - 38 . (canceled) 
     
     
         39 . The device of  claim 16 , wherein said composition comprises a pharmaceutically acceptable carrier. 
     
     
         40 . The device of  claim 16 , wherein said composition comprises an agent selected from a permeation enhancer, a polymer capable of increasing mucosal adhesion of the composition, or a combination thereof. 
     
     
         41 . The device of  claim 16 , wherein said unit dose is about 20 mg of atomized ketamine per 0.1 cc spray.